Article

Pemphigus Vulgaris in Pregnancy

Cutis. 2014 October;94(4):206-209

References

1. Fainaru O, Mashiach R, Kupferminc M, et al. Pemphigus vulgaris in pregnancy: a case report and review of literature. Hum Reprod. 2000;15:1195-1197.

2. Joly P, Gilbert D, Thomine E, et al. Identification of a new antibody population directed against a desmosomal plaque antigen in pemphigus vulgaris and pemphigus foliaceus. J Invest Dermatol. 1997;108:469-475.

3. Daniel Y, Shenhav M, Botchan A, et al. Pregnancy associated with pemphigus. Br J Obstet Gynecol. 1995;102:667-669.

4. Ruach M, Ohel G, Rahav D, et al. Pemphigus vulgaris and pregnancy. Obstet Gynecol Surv. 1995;50:755-760.

5. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on clinical course of pemphigus vulgaris. J Am Acad Dermatol. 1996;34:645-652.

6. Goldberg NS, DeFeo C, Kirshenbaum N. Pemphigus and pregnancy: risk factors and recommendations. J Am Acad Dermatol. 1993;28(5, pt 2):877-879.

7. Lehman JS, Mueller KK, Schraith DF. Do safe and effective treatment options exist for patients with active pemphigus vulgaris who plan conception and pregnancy? Arch Dermatol. 2008;144:783-785.

8. Kardos M, Levine D, Gurcan H, et al. Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes. Obstet Gynecol Surv. 2009;64:739-749.

9. Fenniche S, Benmously R, Marrak H, et al. Neonatal pemphigus vulgaris in an infant born to a mother with pemphigus vulgaris in remission. Pediatr Dermatol. 2006;23:124-127.

10. Kalayciyan A, Engin B, Serdaroglu S, et al. A retrospective analysis of patients with pemphigus vulgaris associated with pregnancy. Br J Dermatol. 2002;147:396-397.

11. Hup JM, Bruinsma RA, Boersma ER, et al. Neonatal pemphigus vulgaris: transplacental transmission of antibodies. Pediatr Dermatol. 1986;3:468-472.

12. Piontek JO, Borberg H, Sollberg S, et al. Severe exacerbation of pemphigus vulgaris in pregnancy: successful treatment with plasma exchange. Br J Dermatol. 2000;143:455-456.

13. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008;47:292-294.

14. Marzano AV, Fanoni D, Venegoni L, et al. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology. 2007;214:310-318.

15. Braunstein I, Werth V. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatol Ther. 2013;26:354-363.

16. Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499-1506.

Comment

Pemphigus vulgaris is associated with infertility in its active phase; therefore, PV during pregnancy is rare.⁸ Pregnancy may exacerbate PV, which has been a similar finding in other well-documented autoimmune diseases.⁷ One review of PV in pregnancy reported that 11 of 49 patients (22%) experienced an exacerbation of the disease.⁸ This finding pre-sents 2 problems: (1) severe active disease during pregnancy with high antibody titers has been shown to heighten risk for morbidity and mortality for the fetus, and (2) a patient with active PV during pregnancy may require systemic therapy with doses high enough to subdue the disease. The presence of PV was a challenge throughout our patient’s pregnancy. Transient skin lesions may occasionally appear in the neonate and seem to have an increased association with severe active PV in the mother; however, neonatal PV also has been present in mild cases in the mother.⁷ These lesions are secondary to passive transplacental transfer of PV antibodies but do not have long-lasting clinical implications because of an antibody’s brief half-life.⁹ The lesions either spontaneously resolve or can be treated with a topical corticosteroid.

Treatment with high-dose systemic corticosteroids or immunosuppressants can be problematic because of the risks posed to the fetus, especially if the mother must be treated when the embryo is particularly susceptible (eg, during organogenesis).¹⁰ If a woman with known PV is planning to become pregnant, it is recommended to first control and suppress the disease so that therapy can be minimal during the pregnancy. It also is recommended to use aggressive topical therapy if possible to control PV in a pregnant woman.⁸ This option would not have been efficacious in our patient because of her severe widespread disease.

Prednisone is considered one of the first-line treatments of PV and has been historically successful as a treatment for pregnant patients with PV if maintained at a low dosage. Prednisone, similar to other corticosteroids, can cross the placental barrier and can increase the chance of premature birth, infection, and mortality in high doses.⁷ Similar to prednisone, azathioprine is not recommended during pregnancy, but if use is necessary, it is suggested to keep the dose low to prevent fetal harm.¹¹ Inadequate treatment and control of PV can be life threatening to the patient because of the severe infection that may ensue; thus it is necessary for the health of the patient and fetus to suppress the PV. One alternative to treatment with steroids and immunosuppressants is plasma exchange, which has been successful in the clinical context of pregnancy.¹² The cons of plasma exchange are repeat procedures, the need to give the patient more immunosuppressants to prevent a rejection, and the return of the autoantibody.⁷

Several studies have evaluated the safety and efficacy of rituximab in the treatment of refractory PV. Multiple case reports state that both 1 and 2 courses of intravenous rituximab therapy at a dosage of 375 mg per square meter of body surface area affected once weekly for 4 weeks proved to be useful in clinical improvement for patients with refractory disease.^13,14 Studies are currently underway to look at the effects of rituximab on pregnancy and the fetus. Preliminary findings show neonates may have B-cell abnormalities initially yet recover fully without infectious complications or sequelae.¹⁵ Rituximab currently is a pregnancy category C drug, and women are counseled to avoid pregnancy for at least 12 months after rituximab exposure and use contraception while actively taking the drug.¹⁶

Conclusion

Contrary to traditional thinking, PV itself may be associated with poor neonatal outcome, including prematurity and fetal death. These complications seem to be restricted to pregnancies with clinically severe PV.⁷ Our patient decided to progress with her pregnancy despite the potential risk to the fetus from the disease and treatment. Ultimately, the infant was delivered prematurely but was free of disease.